We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Adaptimmune Nabs Breakthrough Therapy for NY-ESO T-Cell Therapy
AbbVie’s Endometriosis Pain Candidate Meets Primary Endpoints in Phase 3
FDA Grants Priority Review to KemPharm Pain Candidate
Adcomm to Discuss Drug Compounding in March
Chugai’s ALK Inhibitor Trial Stopped Early Due to Benefit